1. Erythropoietin for the prevention of postoperative neurocognitive disorder in older adult patients undergoing total joint arthroplasty: a randomized controlled study.
- Author
-
Kim, Eun Jung, Park, Kwan Kyu, Choi, Su Youn, Ju, Hyang Mi, Kim, Tae Lim, Kim, Jeongmin, Kim, Soo Yeon, and Koo, Bon-Nyeo
- Subjects
PREVENTION of surgical complications ,SURGERY ,PATIENTS ,TOTAL hip replacement ,RESEARCH funding ,PLACEBOS ,ERYTHROPOIETIN ,STATISTICAL sampling ,TREATMENT effectiveness ,RANDOMIZED controlled trials ,DESCRIPTIVE statistics ,SURGICAL complications ,DELIRIUM ,COGNITION disorders ,TOTAL knee replacement ,NEUROPSYCHOLOGICAL tests ,CYTOKINES ,PERIOPERATIVE care ,DISEASE incidence ,C-reactive protein ,OLD age - Abstract
Background: Post-operative delirium (PD) is a common post-operative complication with significant clinical and financial impacts on patients. Erythropoietin (EPO), a multi-functional glycoprotein hormone, exhibits erythropoietic and non-erythropoietic anti-inflammatory properties. This study aimed to determine the role of perioperative EPO administration in the development of postoperative delirium in older adult patients undergoing total joint arthroplasty. Methods: Seventy-one patients (> 65 years old) scheduled for total joint arthroplasty were randomly assigned to two groups: EPO-treated (EPO, n = 35) and placebo (control, n = 36). All patients completed the Mini Mental State Examination (MMSE) pre-operatively and on post-operative day (POD) 2. The confusion assessment method (CAM) was used to assess the patients until discharge (POD 5). Serum C-reactive protein (CRP) and inflammatory cytokine levels were measured and compared pre- and post-operatively. The development of delirium and cognitive dysfunction was evaluated post-operatively. Results: One patient in the control group developed delirium on POD 2 (3.2%), whereas no patient in the EPO group developed PD (0% vs. 3.2%, p = 0.500). Post-operatively there was no significant difference in MMSE scores between groups. Both groups showed increases in pro- and anti-inflammatory cytokine levels, with no significant differences. Similarly, CRP levels, neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) showed no intergroup differences in post-operative inflammatory responses. Conclusions: Perioperative EPO reduced the incidence of post-operative delirium, although not statistically significant, with no differences in post-operative cognitive function and inflammatory responses. Trial registration: The trial was registered on December 12, 2023 at http//clinicaltrials.gov, registration number NCT06178835. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF